Etoricoxib
Active ingredient description
Etoricoxib is an oral, selective cyclo-oxygenase-2 (COX-2) inhibitor within the clinical dose range. Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Medicines
Etoricoxib is the active ingredient of these drugs:
Spain
Italy
Hong Kong
Austria Brazil Cyprus Finland France
New Zealand
Spain
Lithuania
Singapore
Poland
Lithuania
Poland
Hong Kong
Poland
Lithuania
Germany
Germany
Germany
Hong Kong
Hong Kong
Hong Kong
Italy Singapore
Spain
Hong Kong
Brazil
Hong Kong
Poland
Hong Kong
Cyprus
Lithuania
Hong Kong
Poland
Hong Kong
Italy
Hong Kong
Spain
Hong Kong
Poland
Italy
Product monographs
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):
Structural formula
Unique ingredient identifier (UNII)
WRX4NFY03R - ETORICOXIB
CAS registry number
202409-33-4 - etoricoxib
SNOMED-CT
409134009 - Etoricoxib (substance)